Published in Vaccine Weekly, September 10th, 2003
The multiyear agreement grants Apovia commercial rights to RC-529 for use in an undisclosed therapeutic vaccine. Both companies will equally share research, development and commercialization costs, as well as any potential product revenue.
"RC-529 adjuvant is a synthetic adjuvant that has been shown to stimulate immune responses to multiple vaccine antigen formulations both in animal models and in man," said Steven Gillis, PhD, chairman and chief executive officer at Corixa. "We look forward to continuing the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.